Apeloa Pharmaceutical and Hangzhou Apeloa Medicine Research Institute have described new N-(benzoyl)-phenylalanine compounds acting as integrin alpha4beta7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease.